Company / Shareholders' Equity
ADC Therapeutics SA Shareholders' Equity History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$185.8M
FY2025
5-year range
-$185.8M / $79.5M
FY2023-FY2025
Trend
-25.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
ADC Therapeutics SA reports negative total equity of -$186M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$186M in FY2025.
Declined from $79M to -$186M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, shareholders' equity decreased 25.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score -4.83 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$185.8M | -25.4% |
| FY2024 | -$148.2M | -286.6% |
| FY2023 | $79.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026